Irish-based Amryt Pharma gets boost for drug in France
Irish-based drug company Amryt Pharma has said its flagship treatment will now be reimbursed by health authorities in France.
The approval for reimbursement will mean that the drug, Lojuxta, which treats a rare condition that can lead to heart attacks, is now available in five key European countries including Britain, Italy, Germany and Spain.
Analysts at Stifel, which is broker to Amryt, estimate that about 100 people in France have homozygous familial hypercholesterolaemia with about...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Analysis: Zappone row illuminates uncompetitive nature of diplomatic appointments
The optics of a former cabinet colleague being hastily appointed to a prestigious international role are not good for the government, yet a change in policy of how such roles are filled is unlikely any time soon
Analysis: Draft legislation brings individual accountability for financial sector misconduct a step closer
Executives could be fined up to €1 million and barred from working in the sector if they breach financial conduct rules under proposed new law
Analysis: The gap between winners and losers in retail is stark
The ability to adapt to what are likely to be continually changing circumstances will continue to be a hallmark of those who prosper
Vincent Boland: Tycoon space race is boldly going where many have gone before
So far, the space missions of Bezos, Branson and Musk lack the poetics, significance or purpose of Aldrin and Armstrong’s, but it’s early days yet